The bad news for LL was that the improvement in SOC has so dramatically helped severe covid-19 patients, preventing them from advancing to critical and then possibly dying.

So our market for cv19 LL seems clearly to be critical, longhaulers and also mild/moderate. Our m/m data was compelling and should have earned an EUA.